Label: information for the user
RivastigmineViatris4,6 mg/24 h patchstransdermal EFG
rivastigmine
Read this label carefully before starting to use this medication, as it contains important information for you.
The active ingredient of Rivastigmina Viatris is rivastigmina.
Rivastigmina belongs to the group of cholinesterase inhibitors. In patients with Alzheimer's disease, certain nerve cells die in the brain, resulting in low levels of acetylcholine neurotransmitters (a substance that allows nerve cells to communicate with each other). Rivastigmina acts by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase.
By blocking these enzymes, rivastigmina allows for an increase in acetylcholine in the brain, helping to reduce the symptoms of Alzheimer's disease.
Rivastigmina Viatris is used for the treatment of adult patients with mild to moderately severe Alzheimer's disease, a progressive brain disorder that gradually affects memory, intellectual capacity, and behavior.
Do not use Rivastigmina Viatris
If you find yourself in any of these situations, inform your doctor and do not use Rivastigmina Viatris.
Warnings and precautions
Consult your doctor or pharmacist before starting to use Rivastigmina Viatris:
If you find yourself in any of these situations, your doctor may consider the need for closer monitoring while you are on treatment.
Children and adolescents
There is no experience of the use of Rivastigmina Viatris in the pediatric population in the treatment of Alzheimer's disease.
Other medications and Rivastigmina Viatris
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication,including those purchased without a prescription.
Rivastigmina Viatris may increase the effects of some medications that lower blood pressure; for example, "beta blockers", such as atenolol; "calcium channel blockers", such as amlodipine, nifedipine; "antiarrhythmic medications", such as sotalol, amiodarone, digitals, and pilocarpine (used to treat glaucoma). This may cause you to faint.
If you are administered some of the following medications, your doctor may subject you to regular cardiac checks to ensure that you do not have any problems:
Rivastigmina may interfere with anticholinergic medications some of which are medications used to relieve stomach cramps or spasms (for example, dicyclomine), to treat Parkinson's disease (for example, amantadine),to treat an overactive bladder (for example, oxybutynin, tolterodine) or to prevent motion sickness (for example, diphenhydramine, scopolamine, or meclizine).
Rivastigmina Viatris should not be administered at the same time as metoclopramide (a medication used to relieve or prevent nausea and vomiting). Taking the two medications together may cause problems such as stiffness in the limbs and hand tremors.
If you need to undergo surgery while using Rivastigmina Viatris, inform your doctor that you are using it, as you may need to stop it because it may excessively potentiate the effects of some anesthetic muscle relaxants.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication.
If you are pregnant, it is necessary to evaluate the benefits of using Rivastigmina Viatris against the possible adverse effects on the fetus. Rivastigmina Viatris should not be used during pregnancy unless it is clearly necessary.
You should not breastfeed during your treatment with Rivastigmina Viatris.
Driving and operating machinery
Your condition may affect your ability to drive or operate machinery and you should not do so unless your doctor tells you it is safe to do so. Rivastigmina Viatris may cause dizziness and drowsiness, mainly at the beginning of treatment or when increasing the dose. If you experience these effects, you should not drive or operate machinery.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist..
IMPORTANT
How to start treatment
Your doctor will indicate the most suitable dose of Rivastigmina Viatris transdermal patch for your case..
Your doctor may adjust the dose during treatment depending on your individual needs..
If you have not used the patches for three days, do not apply a new one without consulting your doctor, as you may be more prone to experiencing adverse effects. Treatment with a transdermal patch can be restarted with the same dose if treatment is not interrupted for more than three days. Otherwise, your doctor will have you restart your treatment with Rivastigmina Viatris 4.6 mg/24 h.
Where to place Rivastigmina Viatris transdermal patches
Every 24 hours, remove the previous patch before applying a new one inonly oneof the possible areas.
Each time you change the patch, the previous patch should be removed before applying a new one to a different area of the skin (for example, one day on the right side of the body and the next day on the left side; and one day on the chest or upper back and the next day on the lower back). Wait at least 14 days before applying a new patch to the same area of the skin..
How to apply Rivastigmina Viatris
Rivastigmina Viatris patches are thin, orange-colored plastic patches that stick to the skin. Each patch is in a protective envelope that keeps it safe until it is applied. Do not open the envelope or remove the patch from the envelope until you are ready to apply it..
Remove the previous patch carefully before applying a new one..
Patients starting treatment for the first time and patients restarting treatment with rivastigmina after interrupting treatment should start with the second figure..
Each patch is in an individual protective envelope.
Only open the envelope when you are ready to apply the patch.
Open the envelope by cutting along both perforations, without exceeding the indicated line. Tear the envelope to open it. Do not cut the entire length of the envelope to avoid damaging the patch.
Remove the patch from the envelope.
Remove the skin-colored backing from the top of the patch and discard it.
A protective liner covers the adhesive side of the patch.
Remove the first liner without touching the adhesive side of the patch..
Place the adhesive side of the patch on the upper or lower back, or on the arm or chest, and then remove the second liner.
Press the patch firmly against the skin with the palm of your hand for at least 30 seconds and make sure the edges have stuck well.
If this helps, you can write on the patch, for example, the day of the week, with a fine-tip pen..
You should wear the patch continuously until it is replaced with a new one. When applying a new patch, you can try different areas (choosing from the previously mentioned ones) to find the ones that are most comfortable and where clothing does not rub against the patch..
How to remove Rivastigmina Viatris
Gently pull one edge of the patch to slowly remove it from the skin. If there are any remaining adhesive residues on the skin, soak the area with warm water and mild soap or use baby oil to help remove them. Do not use alcohol or other solvents (nail polish removers or other solvents).
Wash your hands
Wash your hands with water and soap after removing or applying the patch. If you come into contact with your eyes or if your eyes become red after handling the patch, wash them immediately with plenty of water and seek medical advice if the symptoms do not resolve.
Can Rivastigmina Viatris be worn when bathing, swimming, or exposed to the sun??
What to do if a patch falls off
If a patch falls off, apply a new one for the rest of the day and replace it the next day at the usual time..
How long and when to wear Rivastigmina Viatris
If you use more Rivastigmina Viatris than you should
If you accidentally apply more than one patch, remove all patches from the skin and inform your doctor or pharmacist, or call the Toxicological Information Service, phone: 91 562 04 20 (indicating the medication and the amount administered). You may need medical attention.
Some people who have accidentally taken too much rivastigmina have experienced a decrease in pupil size (miosis), skin redness, and a sensation of heat (hot flashes), stomach pain, nausea, vomiting, diarrhea, slow heart rate, sudden difficulty breathing (bronchospasm), increased sputum production, increased sweating, incontinence or loss of bowel control, crying, low blood pressure, increased salivation, dizziness, tremors, headaches, drowsiness, confusion, high blood pressure, hallucinations, or general malaise. In severe cases, muscle weakness, uncontrollable muscle tics, seizures, or respiratory arrest or slower breathing have been documented.
What to do if you forget to use Rivastigmina Viatris
If you realize you have forgotten to apply a patch, apply itimmediately. The next day, apply the next patch at the usual time. Do not apply two patches to compensate for the one you forgot..
What to do if you interrupt treatment with Rivastigmina Viatris
Inform your doctor or pharmacist if you stop using the patches..
If you have not used the patches for three days or more, do not apply a new one without consulting your doctor, as you may be more prone to experiencing adverse effects.
If you have any other questions about using this medication, ask your doctor or pharmacist..
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
You may experience side effects more frequently when you start treatment or when your dose is increased. Generally, side effects will slowly disappear as your body gets used to the medicine.
If you notice any of the following serious side effects, remove the patch and immediately inform your doctor:
Other possible side effects may include:
Frequent(may affect up to 1 in 10 people):
Rare(may affect up to 1 in 100 people):
Uncommon(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Frequency not known(cannot be estimated from available data):
Other side effects experienced with rivastigmine capsules or oral solution and that may occur with patches:
Frequent(may affect up to 1 in 10 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Frequency not known(cannot be estimated from available data):
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use, https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the overwrap after CAD. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Store the transdermal patch inside the overwrap until use.
Do not use any patch if you observe that it is damaged or shows signs of manipulation.
After removing a patch, fold it in half with the adhesive side inwards and press. After placing it in the original overwrap, when disposing of the patch ensure it is out of the reach of children. After removing the patch, do not touch your eyes, and wash your hands thoroughly with water and soap.
Medications should not be disposed of through drains or in the trash. Deposit the containers and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medications you no longer need. This will help protect the environment.
Composition of Rivastigmina Viatris
The active ingredient is rivastigmina.
Each patch releases 4.6 mg of rivastigmina in 24 hours, measures 4.6 cm2and contains 6.9 mg of rivastigmina.
The other components are:
Matrix:
Backing layer:
Release layer:
Appearance of the product and contents of the package
Thin transdermal patch. The outer layer is orange and carries the following printed in orange printing ink:
Each package contains a transdermal patch. Patches are available in packages containing 7 or 30 patches and in multi-packages containing 60 or 90 patches. Only some package sizes may be marketed.
Marketing authorization holder and manufacturer responsible
Marketing authorization holder:
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer responsible:
McDermott Laboratories Ltd trading as Gerard Laboratories
35/36 Baldoyle Industrial Estate,
Grange Road, Dublin 13,
Ireland
or
Mylan Hungary Kft
Mylan utca 1
Komárom, 2900
Hungary
or
Luye Pharma AG
Am Windfeld 27 and 35
83714 Miesbach
Germany
Further information on this medicinal product can be obtained by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.U.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicinal product is authorized in the Member States of the European Economic Area with the following names:
GermanyRivastigmin Mylan 4.6 mg/24Hours transdermal patch
BelgiumRivastigmine Mylan 4.6 mg/24 h Plasters for transdermal use
SpainRivastigmina Viatris 4.6 mg/24 h patchestransdermal EFG
FranceRivastigmine Mylan Pharma 4.6 mg/24 h transdermal device
ItalyRivastigmina Mylan Pharma 4.6 mg/24 h
NetherlandsRivastigmin Plaster Mylan 4.6 mg/24 h Plaster for transdermaluse
PolandRivastigmine Mylan
PortugalRivastigmina Mylan
United KingdomEluden 4.6 mg/24 h transdermal patch
Last review date of this leaflet:February 2025
Further detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.